Floatz logo

L-Nmma

DNA Repair-Deficiency Disorders

The Methodist Hospital Research InstitutePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the DNA Repair-Deficiency Disorders cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 3B
Eloxatin
National Cancer Institute (NCI)
Phase 3B
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 3B
METHYLPREDNISOLONE ACETATE IMPURITY E
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2CCC
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2CCC

View all 15 →

Same molecule, other indications

L-Nmma is also rated in:

sickle cell diseaseDormant
BB
Indicative ·
67 / 100
View asset →
triple-negative breast carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
obesity disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →